Diocalm Ultra

Quick links

Choose a section

Quick links to important sections

Advertisements

Diocalm Ultra

Advertisements
Advertisements

Method of action: Antidiarrheal, Obstructive

Treatment option: Irritable Bowel Syndrome

Advertisements

Overview of Diocalm Ultra

Quick Facts

Property Description
Active ingredient Loperamide hydrochloride
Form Capsule, Tablet, oral solution, orodispersible tablet
Pharmacological class Antidiarrheal agent, mu-receptor agonist
Common use Symptomatic control of acute non-specific diarrhea
Origin Synthetic, phenylpiperidine derivative

What Type of Medicine is Diocalm Ultra?

Diocalm Ultra is a synthetic oral medication primarily classified as an antidiarrheal agent. The preparation's active component, Loperamide hydrochloride, is a synthetic phenylpiperidine opioid derivative and an anti-peristaltic agent that acts specifically on the gut. Loperamide is recognized for its fundamental role in diarrhea management. This medicine is often available Over-the-Counter (OTC), positioning it for self-care in managing sudden-onset diarrhea, and its high-level therapeutic purpose is to provide effective symptomatic relief by regulating excessive bowel motility.

Loperamide Hydrochloride: Composition and Form

The medicinal entity is a preparation based solely on the active ingredient, Loperamide hydrochloride, confirming it as a monotherapy. As a synthetic chemical, its structure is designed to confine its effects primarily within the intestinal tract. Diocalm Ultra is intended for oral administration and is typically available in various oral dosage forms, including the standard capsule and tablet. The active ingredient Loperamide is used as an antidiarrheal for its intended application. The active component acts by modulating intestinal motility to decrease intestinal transit time, which addresses the symptoms of diarrhea by allowing the body more time for essential fluid absorption.

Advertisements

What side effects are possible with Diocalm Ultra?

Possible side effects and safety information

The safety profile for Loperamide hydrochloride, the active ingredient in Diocalm Ultra, is formally categorized by regulatory bodies based on frequency and the affected System-Organ Class (SOC).

Adverse reactions are classified according to incidence reported in clinical studies, with classifications typically ranging from Common to Rare.


Frequency-Classified Adverse Reactions

Classification Examples of Documented Adverse Reactions
Common Constipation, Flatulence, Headache, Nausea
Uncommon Dizziness, Abdominal pain, Dry mouth, Skin rash, Dyspepsia
Rare Vomiting, Abdominal distension, Paralytic ileus, Angioedema, Bullous eruptions, Loss of consciousness

These effects fall primarily under Gastrointestinal Disorders and Nervous System Disorders in official safety documentation.

Serious Adverse Reactions and Safety Constraints

Although rare, officially documented serious adverse reactions include paralytic ileus, toxic megacolon, severe bullous skin reactions (such as Toxic Epidermal Necrolysis), and anaphylactic reactions. Furthermore, serious cardiac events (e.g., QT interval and QRS complex prolongation, Torsades de Pointes) are noted, particularly associated with use at doses exceeding the recommended maximum.

Official labeling defines specific safety restrictions. The medicine is contraindicated in conditions where inhibiting peristalsis could lead to severe complications, such as acute dysentery, specific bacterial enterocolitis, or when abdominal distension or ileus is already present. For pediatric patients, use is specifically contraindicated in children under 2 years of age due to heightened risk of respiratory depression and serious adverse events. Caution is also required in individuals with hepatic impairment due to the potential for increased systemic exposure and subsequent CNS toxicity.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Taking more than the recommended dose of Diocalm Ultra (loperamide) can lead to serious and potentially fatal heart problems. These severe adverse events are particularly associated with the misuse and abuse of high doses, often in an attempt to self-treat opioid withdrawal symptoms.

Overdose can affect the cardiovascular and nervous systems. Symptoms may include a fast, pounding, or irregular heartbeat, dizziness, lightheadedness, or fainting. In severe cases, documented clinical manifestations include the prolongation of the QT interval on an electrocardiogram (EKG), which can lead to life-threatening heart rhythms like Torsades de pointes and cardiac arrest. Signs of central nervous system (CNS) or respiratory depression, such as confusion, unresponsiveness, slow or shallow breathing, or pinpoint pupils, may also occur.

Immediate medical attention is required if you experience a fast, irregular, or pounding heartbeat, dizziness, unresponsiveness, or fainting. If the victim has collapsed, is having a seizure, has trouble breathing, or cannot be awakened, call emergency services immediately. Because loperamide can have a longer duration of action, close medical monitoring for at least 48 hours and repeated treatments with an antidote, such as naloxone, may be necessary.

Advertisements

Therapeutic Uses of Diocalm Ultra

Main Uses of Diocalm Ultra

Diocalm Ultra is a medication formulated to provide symptomatic relief for acute episodes of diarrhea. It is primarily used to manage sudden, short-term bouts of loose or watery stools in adults and children over the age of 12.

Mechanism of Action

The active ingredient in this medication works by slowing down the overactive digestive system. When the intestines move too quickly, the body cannot absorb water and nutrients efficiently, leading to diarrhea. By moderating the speed of intestinal contractions, the medication allows more time for the bowel to absorb water and electrolytes, which helps to firm up the stool and reduce the frequency of bowel movements.

Key Benefits

Restoration of Digestive Rhythm

By normalizing the movement of the digestive tract, the medication helps the body return to its natural rhythm. This reduction in intestinal speed is essential for managing the urgency often associated with acute diarrhea.

Management of Fluid Loss

One of the primary physiological benefits of treating diarrhea is the prevention of excessive fluid loss. By slowing the passage of waste through the colon, the medication facilitates better fluid reabsorption, supporting the body's overall hydration levels during an illness.

Symptom Control

Diocalm Ultra focuses on the practical management of symptoms, helping individuals regain control over their bowel function. This can provide physical comfort and reduce the disruption to daily activities caused by frequent toilet visits.

Advertisements

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

The eligibility for Diocalm Ultra (Loperamide hydrochloride) is strictly defined by regulatory documents based on age, underlying conditions, and physiological status.

Eligibility Classification Population/Condition Regulatory Status
Absolute Contraindicated Pediatric patients less than 2 years of age Prohibited due to serious cardiac and respiratory risks.
Absolute Contraindicated Acute dysentery (bloody stool/fever) or colitis Prohibited due to risk of toxic megacolon.
Absolute Contraindicated Abdominal pain in the absence of diarrhea Prohibited.
Use with Caution Patients with hepatic impairment (liver disease) Use with caution; monitor for central nervous system toxicity.
Use with Caution Patients with risk factors for QT prolongation Avoid due to potential serious cardiac adverse reactions.
Not Recommended Pregnancy and Breastfeeding Not recommended due to insufficient human safety data or excretion into breast milk.

Use is approved for adults and children aged 12 years and over for acute diarrhea. The medicine must be discontinued immediately if constipation, ileus, or abdominal distention develops during treatment. No dose adjustment is generally required for elderly patients or those with renal impairment.

Advertisements

What should I know about interactions with other medicines?

️ Interaction Map: Interactions with other medicines and products — official regulatory information for Diocalm Ultra

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions P-glycoprotein and CYP enzyme inhibitors, QT-prolonging agents, and substances with additive CNS effects.
Specific interacting medicines (if explicitly listed) Quinidine, Ritonavir (P-gp inhibitors), Ketoconazole, Itraconazole (CYP3A4/P-gp inhibitor), and Gemfibrozil (CYP2C8 inhibitor).
Mechanistic basis of interactions (only if stated in label) Loperamide is a substrate for the efflux transporter P-glycoprotein (P-gp) and is metabolized by the CYP3A4 and CYP2C8 isoenzymes.
Timing-based interaction rules (if applicable) None documented.
Population-specific interaction notes (if applicable) Hepatic Impairment: Risk of increased systemic exposure and potential CNS toxicity due to reduced first-pass metabolism.
Interaction-related restrictions Co-administration with drugs and herbal products known to prolong the QT interval must be avoided. Alcohol may increase the risk of documented CNS side effects.

Interaction Classifications (High-Level)

Classification Type Official Regulatory Statement
Interaction severity classification (as defined in official documents) Major/Contraindicated (with QT-prolonging agents). Clinically Significant Exposure Increase (with multiple CYP/P-gp inhibitors).
Regulatory basis (EMA / FDA / etc.) Documented in Prescribing Information (FDA) and Summary of Product Characteristics (SmPC) (EMA/HPRA).
Interaction-context constraints (as defined in official documents) Interactions documented to increase plasma levels up to 13-fold or potentiate CNS effects.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration of P-gp inhibitors (e.g., Quinidine) results in a documented 2- to 3-fold increase in Loperamide plasma levels.
  • The combination of the CYP3A4/P-gp inhibitor Itraconazole and the CYP2C8 inhibitor Gemfibrozil results in a 12.6-fold increase in total plasma exposure (AUC).
  • Drugs with similar pharmacological properties may potentiate Loperamide's effect, increasing the risk of documented Central Nervous System (CNS) depression.

Connection to the overall interaction profile (2–4 sentences):

Official regulatory documents define Loperamide's interaction profile by identifying substances that affect its clearance via CYP3A4, CYP2C8, and P-gp pathways, resulting in substantial increases in systemic exposure. The profile also sets a strict restriction against co-administration with any agents that may prolong the QT interval due to the documented risk of serious cardiac adverse events.

Advertisements

Mechanism of Action

Targeted Agonism of Intestinal mu-Opioid Receptors

The mechanism of Loperamide begins with its agonism (activation) of mu-opioid receptors located on the nerve endings of the myenteric plexus in the intestinal wall. This interaction is highly localized and peripheral and modulates activity within the Enteric Nervous System by inhibiting the release of excitatory neurotransmitters like Acetylcholine and Prostaglandins.


Modulation of Propulsive Motility and Transit Time

The resulting inhibition of nerve signaling directly leads to a suppression of propulsive peristalsis, which is the coordinated muscular wave that moves contents forward. By slowing this motility, the drug initiates a physiological cascade that prolongs the intestinal transit time, which is the necessary condition for its subsequent effects on fluid balance.


Increased Fluid and Electrolyte Reabsorption

The extended residence time, coupled with an influence on mucosal transport mechanisms, increases the passive and active reabsorption of water and electrolytes from the intestinal lumen. This physiological consequence changes the intestinal fluid-exchange dynamics and is the key step that shapes the final physiological consequence.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Diocalm Ultra (Loperamide hydrochloride) is administered orally and is commonly available as capsules, tablets, or oral solution. The standard strength for solid forms is typically 2 mg.


Dosing Patterns and Limits

The standard protocol for acute symptom management involves as-needed dosing following each unformed stool. Adult treatment begins with an initial dose of 4 mg (two 2 mg units). A subsequent dose of 2 mg is then taken after each loose stool. For self-care, the maximum daily dose is generally restricted to 8 mg within a 24-hour period. Under medical supervision, the maximum dose for supervised treatment may be higher, ranging up to 16 mg per day. For chronic conditions, the dosing is adjusted to achieve a maintenance regimen that results in one to two formed stools daily.


Contextual Use and Duration

Administration must be accompanied by the intake of adequate clear fluids and electrolytes. For acute, self-managed use, treatment should not continue for more than 48 hours (2 days). Continued use beyond this period is restricted to guidance from a healthcare professional. The medication must be discontinued immediately if signs of intestinal obstruction, such as abdominal distention or constipation, develop.


Population Rules

Dosage adjustment is not required for older adults. Use must be conducted with caution in patients with hepatic impairment. The medication is not recommended for children under 2 years of age, and specific age- and weight-based schedules must be adhered to for children 2 to 12 years.

Advertisements

Recent Clinical Evidence

Research Evidence for Acute Diarrhea

Research has examined Diocalm Ultra primarily in short-term Randomized Controlled Trials (RCTs) focusing on acute, non-specific diarrhea in adult and older pediatric populations. These studies monitored outcomes such as the overall duration of the diarrheal episode and changes in stool frequency. Findings from systematic reviews describe patterns where the median time to symptom resolution measured in the Diocalm Ultra group was reported as shorter than the time measured in the placebo group. The research landscape is subject to limitations, including varied criteria for defining resolution across studies and limited insight into outcomes for patients presenting with severe or bloody diarrhea, as these groups were generally excluded from pivotal trials.


Evidence for Traveler's Diarrhea and Chronic Conditions

Diocalm Ultra was also evaluated in studies focusing on Traveler's Diarrhea, often in combination with antibiotics. Research described observations where the inclusion of the medicine appeared to be linked to a shorter duration of the episode compared to antibiotics alone. For chronic conditions, such as diarrhea-predominant Irritable Bowel Syndrome (IBS-D), trials reported outcomes related to functional imbalance, with reported improvements in stool consistency compared to baseline. However, studies monitoring IBS-D patients observed that a subgroup reported an increase in abdominal pain.


Long-Term Outcomes and Uncertainty

There is limited information for long-term outcomes regarding the sustained maintenance of observed patterns, as follow-up durations were restricted in most pivotal trials. Furthermore, evidence in specific patient groups, such as very young children (generally under 3 years), remains insufficient, as the research base for outcomes in this cohort is not well characterized. Comparative evidence is lacking in many areas, meaning it is not always possible to draw conclusions about how the medicine compares to all other available options.

Key Studies & References

  1. Loperamide Hydrochloride (Imodium A-D) Human OTC Drug Label: General Indications and Warnings
  2. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (IBS-D section)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Diocalm Ultra (FAQ)


Q: What is the FDA classification or regulatory status of Diocalm Ultra?

According to regulatory information, the active ingredient in Diocalm Ultra, Loperamide, is regulated by the FDA. It is available for use under two regulatory pathways: as an over-the-counter (OTC) medicine and as a prescription (Rx) medication, depending on the dose and packaging.


Q: Is Diocalm Ultra considered a prescription drug or an OTC medicine?

The active ingredient is available in both forms. Official documentation indicates that Loperamide is available in lower strengths for acute, self-care use as an over-the-counter medicine. For specific chronic conditions or higher strengths, it is typically managed as a prescription medication under the guidance of a healthcare professional.


Q: What is the therapeutic area or disease class Diocalm Ultra belongs to?

Diocalm Ultra is classified as an antidiarrheal agent or a gastrointestinal motility modulator. This classification indicates that its primary purpose is to help decrease the frequency of diarrhea.


Q: Has Diocalm Ultra been approved by the European Medicines Agency (EMA) or other international bodies?

Yes. Products containing the active ingredient Loperamide have been granted marketing authorization in Europe via procedures involving the EMA/national agencies. This indicates its formal acceptance and approval for use in those regions.


Q: Is Diocalm Ultra intended for long-term treatment or short-term use?

The official duration of self-treatment for acute diarrhea is generally restricted to no more than two days (48 hours). Chronic use for conditions like IBS-D is described in official documents, but this always occurs under ongoing medical supervision.


Q: How long does it typically take to feel the effects of Diocalm Ultra?

Studies show that the peak concentration of the active ingredient in the bloodstream is reached relatively quickly. Depending on the formulation (capsule or solution), this peak is typically reached between 2.5 and 5 hours after taking the medicine.


Q: How long does Diocalm Ultra stay in your system after stopping use?

The official elimination half-life of the active ingredient, which determines how long the medicine remains in the system, is reported in regulatory documents to be approximately 9 to 14 hours. It is removed from the body primarily through the liver.


Q: Is it necessary to take Diocalm Ultra every day to maintain its effect?

For acute diarrhea, official documents state the medicine is used as needed following a loose stool. For chronic conditions, a maintenance dose is adjusted to achieve one to two formed stools daily, meaning the routine is determined by the condition and the patient's medical supervision.


Q: Does Diocalm Ultra build up in the body over time?

The drug is rapidly metabolized by the liver. Official regulatory warnings state that when the drug is used at doses exceeding recommended limits, there is a documented risk of the drug accumulating in the system and potentially leading to serious adverse effects.


Q: Is Diocalm Ultra an anti-inflammatory medication?

No. Loperamide is classified as an antidiarrheal agent that primarily slows gut motility. It is not classified as an anti-inflammatory drug.


Q: Is it normal to feel dizzy or lightheaded when first taking Diocalm Ultra?

Dizziness is listed in the official safety profile as an uncommon side effect. When dizziness or drowsiness (somnolence) occurs, official documents caution that patients are advised to avoid tasks requiring concentration and alertness, such as driving.


Q: Can taking Diocalm Ultra affect driving ability or alertness?

Official regulatory warnings state that due to potential side effects such as dizziness, drowsiness, and even rare instances of loss of consciousness, patients should be cautioned about performing tasks that require mental alertness, such as driving or operating machinery.


Q: Are there any warnings about using Diocalm Ultra if I have kidney problems?

Official regulatory documents state that no dosage adjustment is required for patients with mild to severe renal (kidney) impairment. This means the specific use conditions related to kidney function are described in the product label.

--רת### Q: Can taking Diocalm Ultra cause skin issues or a rash?

Yes. Official regulatory documents list skin rash as an uncommon adverse reaction, meaning it occurs in less than 1% of patients in studies. More severe skin issues, such as bullous eruptions, are noted as rare, serious adverse events.


Q: Are there any known food restrictions or dietary changes needed with Diocalm Ultra?

Official information states that the administration of the medicine should include the intake of adequate clear fluids and electrolytes to prevent dehydration. However, specific dietary restrictions on particular foods to be avoided are not listed in the official documents.


Q: Does Diocalm Ultra interact with vitamin supplements or herbal remedies?

Official regulatory information states there is a restriction against co-administration with herbal products known to prolong the QT interval due to the risk of serious cardiac events. The interaction status of general vitamins or other common supplements is not explicitly stated in the official label.


Q: Does Diocalm Ultra have any known potential for dependency or withdrawal described in official sources?

While the active ingredient works on opioid receptors, it was removed from controlled substance schedules due to its limited central activity at recommended doses. However, regulatory warnings note the potential for physical dependence and abuse at high doses.


Q: Does Diocalm Ultra show up on drug screening tests?

Loperamide is not typically detected by routine drug screening tests, but it can be identified by specialized laboratory tests.


Q: What is the difference between a contraindication and a precaution for Diocalm Ultra?

A contraindication is defined in regulatory documents as a condition where the drug is not permitted for use (e.g., children under 2 years). A precaution or warning indicates a condition where use requires caution, risk monitoring, or potential dose adjustment (e.g., hepatic impairment).


Q: Is Diocalm Ultra described as safe to use during pregnancy or breastfeeding in official sources?

Official documents state that the drug is generally not recommended during pregnancy because there is insufficient data to confirm its safety in that population. During breastfeeding, its use is described as compatible in official sources, as only tiny amounts of the active ingredient pass into breast milk.


Q: Does the research evidence for Diocalm Ultra involve large-scale human trials?

Official documents cite evidence from short-term Randomized Controlled Trials (RCTs) conducted in adult and older pediatric populations. These RCTs are human trials that follow strict protocols and monitored specific outcomes like the duration of diarrhea.


Q: Are there any recent post-market studies published about Diocalm Ultra?

Yes. Regulatory agencies frequently publish safety updates and post-market analyses to monitor the drug's safety profile in the general population. This has specifically included warnings and new information concerning the misuse of high doses and associated cardiac toxicity.


Q: How is the effectiveness of Diocalm Ultra measured in clinical studies?

According to the Summary of Product Characteristics (SmPC) for the drug, effectiveness in clinical studies is primarily measured by outcomes such as the overall duration of the diarrheal episode and the change in stool frequency compared to baseline or a placebo group.


Q: Why is a patient medication guide required for Diocalm Ultra?

Medication guides are required to inform patients about the risk of serious adverse reactions, particularly the potential for cardiac events and CNS effects when the medicine is used incorrectly or at doses higher than recommended.


Q: Where can I find the official prescribing information for Diocalm Ultra?

The official Prescribing Information and the Patient Medication Guide for the drug are published by the drug’s manufacturer and are available on regulatory databases such as the FDA's DailyMed and the European SmPC repositories. These documents contain the full, most current details about its use and safety.


Q: What should be done with expired Diocalm Ultra according to guidelines?

Official guidelines from regulatory bodies describe methods for disposal, stating that expired medicine is generally recommended for community drug take-back programs. If this is unavailable, the guidelines permit disposal in household trash after mixing it with an undesirable substance like dirt or coffee grounds.


Q: How does Diocalm Ultra affect sleep patterns?

Adverse events related to the nervous system include headache, dizziness, and somnolence (drowsiness). Changes to sleep patterns specifically are not documented in the frequency tables.


Q: Is fatigue a common side effect of Diocalm Ultra?

Fatigue is listed as a rare adverse reaction in regulatory documents, with an incidence of less than 0.1% in clinical studies.


Q: Does Diocalm Ultra impact blood pressure readings?

Loperamide at doses exceeding the recommended maximum is associated with serious cardiac events (e.g., QT prolongation) which affect heart function. Effects on blood pressure are not directly noted as a common side effect.


Q: What is the difference between Diocalm Ultra and the original Diocalm formulation?

Official regulatory documents focus only on the approved formulation of Diocalm Ultra and do not provide comparative statements or details regarding its original formulation or brand differences.


Q: Can Diocalm Ultra be used by teenagers or children?

Official regulatory documents state the medicine is strictly contraindicated for children under 2 years and provide specific schedules for children 2 to 12 years of age. For teenagers (typically 13 years and older), the use is generally described in relation to the adult use conditions.

Advertisements

How should Diocalm Ultra be stored and disposed of?

How to Store and Dispose of Diocalm Ultra?

The storage and disposal instructions for Diocalm Ultra, which contains loperamide hydrochloride, are strictly defined by regulatory labeling.


Storage Conditions

Requirement Condition
Temperature Store at 20 C to 25 C (68 F to 77 F) mathbfOR below 30 C
Protection Keep protected from light and moisture and avoid excessive heat above 40 C
Container Store in the original container and keep it tightly closed
Child Safety Must be kept out of the sight and reach of children

Disposal Instructions

Do not use the product after the expiration date. Any unused or expired Diocalm Ultra must be disposed of in accordance with local requirements for pharmaceutical waste. Disposal should generally be done through an approved waste disposal system and should not be thrown into the household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diocalm Ultra found in:

A-Z Index: